{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T21:07:59Z","timestamp":1783544879590,"version":"3.55.0"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,11,20]],"date-time":"2007-11-20T00:00:00Z","timestamp":1195516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2007,11,28]]},"DOI":"10.1007\/s11764-007-0038-6","type":"journal-article","created":{"date-parts":[[2007,11,19]],"date-time":"2007-11-19T16:55:02Z","timestamp":1195491302000},"page":"261-274","source":"Crossref","is-referenced-by-count":35,"title":["Endocrine sequelae of cancer and cancer treatments"],"prefix":"10.1007","volume":"1","author":[{"given":"Charles J.","family":"Stava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Vassilopoulou-Sellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,11,20]]},"reference":[{"key":"38_CR1","volume-title":"From cancer patient to cancer survivor lost in transition.","author":"M Hewitt","year":"2006","unstructured":"Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor lost in transition.. 1st ed. Washington, DC: National Academies; 2006.","edition":"1"},{"key":"38_CR2","first-page":"1193","volume":"13","author":"C Stava","year":"2005","unstructured":"Stava C, Beck M, Schultz PN, Vassilopoulou-Sellin R. Hearing loss among cancer survivors. Oncol Rep 2005;13:1193\u20139.","journal-title":"Oncol Rep"},{"key":"38_CR3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.coc.0000175291.51232.48","volume":"28","author":"C Stava","year":"2005","unstructured":"Stava C, Beck M, Vassilopoulou-Sellin R. Cataracts among cancer survivors. Am J Clin Oncol 2005;28:603\u20138.","journal-title":"Am J Clin Oncol"},{"key":"38_CR4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/cncr.11897","volume":"100","author":"PN Schultz","year":"2004","unstructured":"Schultz PN, Stava C, Beck ML, Vassilopoulou-Sellin R. Ethnic\/racial influences on the physiologic health of cancer survivors. Cancer 2004;100:156\u201364.","journal-title":"Cancer"},{"key":"38_CR5","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/cncr.22200","volume":"107","author":"CJ Stava","year":"2006","unstructured":"Stava CJ, Lopez A, Vassilopoulou-Sellin R. Health profiles of younger and older breast cancer survivors. Cancer 2006;107:1752\u20139.","journal-title":"Cancer"},{"key":"38_CR6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3816\/CBC.2006.n.034","volume":"7","author":"C Stava","year":"2006","unstructured":"Stava C, Weiss LT, Vassilopoulou-Sellin R. Health profiles of 814 very long-term breast cancer survivors. Clin Breast Cancer 2006;7:228\u201336.","journal-title":"Clin Breast Cancer"},{"key":"38_CR7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2702.2004.01030.x","volume":"14","author":"PN Schultz","year":"2005","unstructured":"Schultz PN, Klein MJ, Beck ML, Stava C, Sellin RV. Breast cancer: relationship between menopausal symptoms, physiologic health effects of cancer treatment and physical constraints on quality of life in long-term survivors. J Clin Nurs 2005;14:204\u201311.","journal-title":"J Clin Nurs"},{"key":"38_CR8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-2407-6-95","volume":"6","author":"C Stava","year":"2006","unstructured":"Stava C, Beck M, Lopez A, Vassilopoulou-Sellin R. Health Profiles of 996 Melanoma Survivors: the MD Anderson Experience. BMC Cancer 2006;6:95.","journal-title":"BMC Cancer"},{"key":"38_CR9","first-page":"102","volume":"1","author":"C Stava","year":"2007","unstructured":"Stava C, Beck ML, Feng L, Lopez A, Busaidy N, Vassilopoulou-Sellin R. Diabetes mellitus among cancer survivors. J Can Surviv 2007;1:102\u2013115.","journal-title":"J Can Surviv"},{"key":"38_CR10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hed.10217","volume":"25","author":"PN Schultz","year":"2003","unstructured":"Schultz PN, Stava C, Vassilopoulou-Sellin R. Health profiles and quality of life of 518 survivors of thyroid cancer. Head Neck 2003;25:349\u201356.","journal-title":"Head Neck"},{"key":"38_CR11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ecl.2005.04.008","volume":"34","author":"LE Cohen","year":"2005","unstructured":"Cohen LE. Endocrine late effects of cancer treatment. Endocrinol Metab Clin North Am 2005;34:769\u201389.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"38_CR12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1210\/edrv.19.2.0328","volume":"19","author":"SC Yeung","year":"1998","unstructured":"Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 1998;19:144\u2013172.","journal-title":"Endocr Rev"},{"key":"38_CR13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/1363849021000039407","volume":"5","author":"MFH Brougham","year":"2002","unstructured":"Brougham MFH, Kelnar CJH, Wallace WHB. The late endocrine effects of childhood cancer treatment. Pediatr Rehab 2002;5:191\u2013201.","journal-title":"Pediatr Rehab"},{"key":"38_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1651-2227.1999.tb14395.x","volume":"88","author":"CA Sklar","year":"1999","unstructured":"Sklar CA. Overview of the effects of cancer therapies; the nature, scale and breadth of the problem. Acta Paediatr Suppl 1999;88:1\u20134.","journal-title":"Acta Paediatr Suppl"},{"key":"38_CR15","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.ejca.2005.02.036","volume":"41","author":"HM Santen Van","year":"2005","unstructured":"Van Santen HM, de Kraker K, Vulsma T. Endocrine late effects from mult-modality treatment of neuroblastoma. Eur J Cancer 2005;41:1767\u201374.","journal-title":"Eur J Cancer"},{"key":"38_CR16","first-page":"55","volume":"17","author":"SR Rose","year":"2004","unstructured":"Rose SR, Schreiber RE, Kearney NS, Lustig RH, Danish RK, Burghen GA, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab 2004;17:55\u201366.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"38_CR17","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1210\/jcem.83.12.5300","volume":"83","author":"GA Kaltsas","year":"1998","unstructured":"Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 1998;83:4233\u201338.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl A","key":"38_CR18","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.ghir.2004.03.038","volume":"14","author":"AA Toogood","year":"2004","unstructured":"Toogood AA. Endocrine consequences of brain irradiation. Growth Horm IGF Res 2004;14(Suppl A):S118\u201324.","journal-title":"Growth Horm IGF Res"},{"key":"38_CR19","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1210\/jc.2005-1525","volume":"90","author":"A Agha","year":"2005","unstructured":"Agha A, Sherlock M, Brennan S, O, Connor SA, O, Sullivan E, Rogers B, et al. Hypothalamic-pituitary dysfunction after irradiation of non-pituitary brain tumors in adults. J Clin Endocrinol Metab 2005;90:6355\u201360.","journal-title":"J Clin Endocrinol Metab"},{"key":"38_CR20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0002-9343(02)01323-2","volume":"114","author":"LB Concha","year":"2003","unstructured":"Concha LB, Carlson HE, Heimann A, Lake-Bakaar GV, Paal AF. Interferon-induced hypopituitarism. Am J Med 2003;114:161\u20133.","journal-title":"Am J Med"},{"key":"38_CR21","first-page":"93","volume":"45","author":"WB Chan","year":"2004","unstructured":"Chan WB, Cockram CS. Panhypopituitarism in association with interferon-alpha treatment. Singap Med J 2004;45:93\u20134.","journal-title":"Singap Med J"},{"key":"38_CR22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00066-007-1706-1","volume":"183","author":"T Langsenlehner","year":"2007","unstructured":"Langsenlehner T, Stiegler C, Quehenberger F, Feigl GC, Jakse G, Mokry M, et al. Long-term follow up of patients with pituitary macroadenomas after postoperative radiation therapy: analysis of tumor control and functional outcome. Strahlenther Onkol 2007;183:241\u20137.","journal-title":"Strahlenther Onkol"},{"key":"38_CR23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2265.2005.02199.x","volume":"62","author":"G Minniti","year":"2005","unstructured":"Minniti G, Jaffrain-Rea M, Osti M, Esposito V, Santoro A, Solda F, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol 2005;62:210\u20136.","journal-title":"Clin Endocrinol"},{"key":"38_CR24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000185357","volume":"47","author":"SE Oberfield","year":"1997","unstructured":"Oberfield SE, Nirenberg A, Allen JC, Cohen H, Donahue B, Prasad V, et al. Hypothalamic\u2013pituitary\u2013adrenal function following cranial irradiation. Horm Res 1997;47:9\u201316.","journal-title":"Horm Res"},{"key":"38_CR25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mpo.10267","volume":"40","author":"HA Spoudeas","year":"2003","unstructured":"Spoudeas HA, Charmandari E, Brook CG. Hypothalamo-pituitary-adrenal axis integrity after cranial irradiation for childhood posterior fossa tumours. Med Pediatr Oncol 2003;40:224\u20139.","journal-title":"Med Pediatr Oncol"},{"key":"38_CR26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2796.1995.tb00907.x","volume":"238","author":"JB Sorensen","year":"1995","unstructured":"Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 1995;238:97\u2013110.","journal-title":"J Intern Med"},{"key":"38_CR27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1006\/gyno.2002.6788","volume":"87","author":"K Ishii","year":"2002","unstructured":"Ishii K, Aoki Y, Sasaki M, Tanaka K. Syndrome of inappropriate secretion of antidiuretic hormone induced by intraarterial cistplatin therapy. Gynecol Oncol 2002;87:150\u20131.","journal-title":"Gynecol Oncol"},{"key":"38_CR28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/03655230410018318","volume":"554","author":"M Kusuki","year":"2004","unstructured":"Kusuki M, Iguchi H, Nakamura A, Nishiura H, Kanazawa A, Yamane H. The syndrome of inappropriate antidiuretic hormone secretion associated with chemotherapy for hypophayryngeal cancer. Acta Otolaryngol Suppl 2004;554:74\u20137.","journal-title":"Acta Otolaryngol Suppl"},{"key":"38_CR29","first-page":"107","volume":"32","author":"Y Yamomoto","year":"2005","unstructured":"Yamomoto Y, Kokubo A, Yonekawa M, Nakanishi K. Syndrome of inappropriate secretion of antidiuretic hormone suddenly occurring in a case following chemotherapy. Gan To Kagaku Ryoho 2005;32:107\u20139.","journal-title":"Gan To Kagaku Ryoho"},{"key":"38_CR30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2169\/internalmedicine.35.290","volume":"35","author":"F Otsuka","year":"1996","unstructured":"Otsuka F, Hayashi Y, Ogura T, Hayakawa N, Ikeda S, Makino H, et al. Syndrome of inappropriate secretion of antidiuretic hormone following intrathoracic cisplatin. Intern Med 1996;35:290\u20134.","journal-title":"Intern Med"},{"key":"38_CR31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/thx.35.8.635","volume":"35","author":"C Robinson","year":"1980","unstructured":"Robinson C, Jeffries RC, Walsh GC. Inappropriate ADH secretion caused by oat cell carcinoma and relieved by lung resection. Thorax 1980;35:635\u20137.","journal-title":"Thorax"},{"key":"38_CR32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/ndt\/13.6.1547","volume":"13","author":"A Negro","year":"1998","unstructured":"Negro A, Regolisti G, Perazzoli F, Davili S, Sani C, Rossi E. Ifosfamide-induced renal Franconi syndrome with associated nephrogenic diabetes insipidus in an adult patient. Nephrol Dial Transplant 1998;13:1547\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"38_CR33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/08860229509037619","volume":"17","author":"R Rossi","year":"1995","unstructured":"Rossi R, G\u00f6dde A, Kleinebrand A, Rath B, J\u00fcrgens H. Concentrating capacity in ifosfamide-induced severe renal dysfunction. Ren Fail 1995;17:551\u20137.","journal-title":"Ren Fail"},{"key":"38_CR34","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(96)03480-0","volume":"348","author":"R Sinner","year":"1996","unstructured":"Sinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996;348:578\u201380.","journal-title":"Lancet"},{"key":"38_CR35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/gut.12.9.717","volume":"12","author":"IM Murray-Lyon","year":"1971","unstructured":"Murray-Lyon IM, Cassar J, Coulson R, Williams R, Ganguli PC, Edwards JC, et al. Further studies on streptozotocin therapy for a multiple-hormone producing islet cell carcinoma. Gut 1971;12:717\u201320.","journal-title":"Gut"},{"key":"38_CR36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0272-6386(87)80166-X","volume":"9","author":"V Delaney","year":"1987","unstructured":"Delaney V, de Pertuz Y, Nixon D, Bourke E. Indomethacin in streptozocin-induced nephrogenic diabetes insipidus. Am J Kidney Dis 1987;9:79\u201383.","journal-title":"Am J Kidney Dis"},{"key":"38_CR37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1677\/erc.1.00779","volume":"11","author":"HK Gleeson","year":"2004","unstructured":"Gleeson HK, Shalet SM. The impact of cancer therapy on the endocrine system in survivors of childhood brain tumors. Endocr Relat Cancer 2004;11:589\u2013602.","journal-title":"Endocr Relat Cancer"},{"key":"38_CR38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0003-4266(06)72602-6","volume":"67","author":"F Borson-Chazot","year":"2006","unstructured":"Borson-Chazot F, Brue T. Pituitary deficiency after brain radiation therapy. Ann Endocrinol (Paris) 2006;67:303\u20139.","journal-title":"Ann Endocrinol (Paris)"},{"key":"38_CR39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.0004-8461.2003.01237.x","volume":"48","author":"A Bhansali","year":"2004","unstructured":"Bhansali A, Banerjee AK, Chanda A, Singh P, Sharma SC, Mathuriya SN, et al. Radiation-induced brain disorders in patients with pituitary tumors. Australas Radiol 2004;48:339\u201346.","journal-title":"Australas Radiol"},{"key":"38_CR40","first-page":"1107","volume":"48","author":"VP Jyotsna","year":"2000","unstructured":"Jyotsna VP, Singh SK, Chaturvedi R, Neogi B, Bhadada SK, Sahay RK, et al. Cranial irradiation- an unusual case for diabetes insipidus. J Assoc Physicians India 2000;48:1107\u20138.","journal-title":"J Assoc Physicians India"},{"key":"38_CR41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1651-2227.1999.tb14396.x","volume":"88","author":"RD Murray","year":"1999","unstructured":"Murray RD, Brennan BM, Rahim A, Shalet SM. Survivors of childhood cancer: long-term endocrine and metabolic problems dwarf the growth disturbance. Acta Paediatr Suppl 1999;88:5\u201312.","journal-title":"Acta Paediatr Suppl"},{"key":"38_CR42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mpo.2950250208","volume":"25","author":"J Rom\u00e1n","year":"1995","unstructured":"Rom\u00e1n J, Villaiz\u00e1n CJ, Garc\u00eda-Foncillas J, Azcona C, Salvador J, Sierrases\u00famaga L. Chemotherapy-induced growth hormone deficiency in children with cancer. Med Pediatr Oncol 1995;25:90\u20135.","journal-title":"Med Pediatr Oncol"},{"key":"38_CR43","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/1097-0142(19921001)70:7<2013::AID-CNCR2820700734>3.0.CO;2-J","volume":"70","author":"JS Olshan","year":"1992","unstructured":"Olshan JS, Gubernick J, Packer RJ, D, Angio GJ, Goldwein JW, Willi SM, et al. The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 1992;70:2013\u20137.","journal-title":"Cancer"},{"key":"38_CR44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/mpo.2950190409","volume":"19","author":"I Marky","year":"1991","unstructured":"Marky I, Mellander L, Lannering B, Albertsson-Wikland L. A longitudinal study of growth and growth hormone secretion in children during treatment for acute lymphoblastic leukemia. Med Pediatr Oncol 1991;19:258\u201364.","journal-title":"Med Pediatr Oncol"},{"key":"38_CR45","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1365-2265.1998.00438.x","volume":"48","author":"BM Brennan","year":"1998","unstructured":"Brennan BM, Rahim A, Mackie EM, Eden OB, Shalet SM. Growth hormone status in adults treated for acute lymphoblastic leukemia in childhood. Clin Endocrinol (Oxf) 1998;48:777\u201383.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"38_CR46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1440-1754.2005.00533.x","volume":"41","author":"R Hameed","year":"2005","unstructured":"Hameed R, Zacharin MR. Long-term endocrine effects of cancer treatment: experience of the Royal Children\u2019s Hospital Melbourne. J Paediatr Child Health 2005;41:36\u201342.","journal-title":"J Paediatr Child Health"},{"key":"38_CR47","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/bjc.1990.138","volume":"61","author":"EA Livesey","year":"1990","unstructured":"Livesey EA, Hindmarsh PC, Brook CG, Whitton AC, Bloom HJ, Tobias JS, et al. Endocrine disorders following treatment for childhood brain tumours. Br J Cancer 1990;61:622\u20135.","journal-title":"Br J Cancer"},{"key":"38_CR48","first-page":"656","volume":"57","author":"M Karasek","year":"2006","unstructured":"Karasek M, Pawlikowski M, Lewinski A. Hyperprolactinemia: causes, diagnosis, and treatment. Endokrynol Pol 2006;57:656\u201362. (article in Polish).","journal-title":"Endokrynol Pol"},{"key":"38_CR49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11102-006-6042-4","volume":"8","author":"KH Darzy","year":"2005","unstructured":"Darzy KH, Shalet SM. Hypopituitarism as a consequence of brain tumors and radiotherapy. Pituitary 2005;8:203\u201311.","journal-title":"Pituitary"},{"key":"38_CR50","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1200\/JCO.1987.5.11.1841","volume":"5","author":"LS Constine","year":"1987","unstructured":"Constine LS, Rubin P, Woolf PD, Doane K, Lush CM. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. J Clin Oncol 1987;5:1841\u201351.","journal-title":"J Clin Oncol"},{"key":"38_CR51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJM199301143280203","volume":"328","author":"LS Constine","year":"1993","unstructured":"Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF, et al. Hypothalamic\u2013pituitary dysfunction after radiation for brain tumors. N Eng J Med 1993;328:87\u201394.","journal-title":"N Eng J Med"},{"issue":"Suppl 2","key":"38_CR52","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1289\/ehp.93101s2109","volume":"101","author":"AL Ogilvy-Stuart","year":"1993","unstructured":"Ogilvy-Stuart AL, Shalet SM. Effect of radiation on the human reproductive system. Environ Health Perspect 1993;101(Suppl 2):109\u201316.","journal-title":"Environ Health Perspect"},{"key":"38_CR53","volume-title":"Cancer medicine","author":"SJ Yeung","year":"2000","unstructured":"Yeung SJ, Gagel RF. Section 40. Complications of cancer and its treatment, 155. Endocrine complications. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Pollock RE, Weischselbaum RR, editors. Cancer medicine. 5th ed. Hamilton, Ontario, Canada: BC Decker Inc.; 2000.","edition":"5"},{"key":"38_CR54","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1210\/jcem-54-6-1164","volume":"54","author":"R Rappaport","year":"1982","unstructured":"Rappaport R, Brauner R, Czernichow P, Thibaud E, Renier D, Zucker JM, et al. Effects of hypothalamic and pituitary irradiation on pubertal development in children with cranial tumors. J Clin Endocrinol Metab 1982;54:1164\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"38_CR55","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1210\/endo-119-3-1185","volume":"119","author":"L Bartalena","year":"1986","unstructured":"Bartalena L, Martino E, Antonelli A, Pacchiarotti A, Robbins J, Pinchera A. Effect of the antileukemic agent l-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (HEP G2) cells. Endocrinology 1986;119:1185\u20138.","journal-title":"Endocrinology"},{"key":"38_CR56","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199512213332507","volume":"333","author":"MI Surks","year":"1995","unstructured":"Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med 1995;333:1688\u201394.","journal-title":"N Engl J Med"},{"key":"38_CR57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/ewjm.172.2.102","volume":"172","author":"BJ Dong","year":"2000","unstructured":"Dong BJ. How medications affect thyroid function. West J Med 2000;172:102\u20136.","journal-title":"West J Med"},{"key":"38_CR58","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.1995.13.4.854","volume":"13","author":"CC Mamby","year":"1995","unstructured":"Mamby CC, Love RR, Lee KE. Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J Clin Oncol 1995;13:854\u20137.","journal-title":"J Clin Oncol"},{"key":"38_CR59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-0029-1210989","volume":"96","author":"SN Djurica","year":"1990","unstructured":"Djurica SN, Ple\u0107as B, Milojevi\u0107 Z, Petrovi\u0107 M, Cirovi\u0107 M, Tasovac-Ponomarev D. Direct effects of cytostatic therapy on the functional state of the thyroid gland and TBG in serum of patients. Exp Clin Endocrinol 1990;96:57\u201363.","journal-title":"Exp Clin Endocrinol"},{"key":"38_CR60","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0360-3016(02)02744-X","volume":"53","author":"AC Paulino","year":"2002","unstructured":"Paulino AC. Hypothyroidism in children with medulloblastoma: a comparison of 3600 and 2340\u00a0cGy craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 2002;53:543\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"38_CR61","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.cji.0000171314.00924.2b","volume":"28","author":"KA Chianese-Bullock","year":"2005","unstructured":"Chianese-Bullock KA, Woodson EM, Tao H, Boerner SA, Smolkin M, Grosh WW, et al. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother 2005;28:412\u20139.","journal-title":"J Immunother"},{"key":"38_CR62","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/eje.1.02104","volume":"154","author":"NL Bohbot","year":"2006","unstructured":"Bohbot NL, Young J, Orgiazzi J, Buffet C, Fran\u00e7ois M, Bernard-Chabert B, et al. Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves\u2019 disease. Eur J Endocrinol 2006;154:367\u201372.","journal-title":"Eur J Endocrinol"},{"key":"38_CR63","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.1993.11.5.921","volume":"11","author":"WH Kruit","year":"1993","unstructured":"Kruit WH, Bolhuis RL, Goey SH, Jansen RL, Eggermont AM, Batchelor D, et al. Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol 1993;11:921\u20134.","journal-title":"J Clin Oncol"},{"key":"38_CR64","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","volume":"92","author":"D Mannavola","year":"2007","unstructured":"Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casari P, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007;92:3531\u20134.","journal-title":"J Clin Endocrinol Metab"},{"key":"38_CR65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","volume":"99","author":"BI Rini","year":"2007","unstructured":"Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81\u20133.","journal-title":"J Natl Cancer Inst"},{"key":"38_CR66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2006.0308","volume":"17","author":"F Wong","year":"2007","unstructured":"Wong F, Rosen LS, Mulay M, Vanvught A, Dinolfo A, Tomoda C, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17:351\u20135.","journal-title":"Thyroid"},{"key":"38_CR67","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","volume":"145","author":"J Desai","year":"2006","unstructured":"Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660\u20134.","journal-title":"Ann Intern Med"},{"key":"38_CR68","doi-asserted-by":"crossref","first-page":"702","DOI":"10.7326\/0003-4819-145-9-200611070-00015","volume":"145","author":"ML Maitland","year":"2006","unstructured":"Maitland ML, Ratain MJ. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med 2006;145:702\u20133.","journal-title":"Ann Intern Med"},{"key":"38_CR69","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ejca.2006.09.015","volume":"42","author":"FA Eskens","year":"2006","unstructured":"Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127\u201339.","journal-title":"Eur J Cancer"},{"key":"38_CR70","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jnci\/djm008","volume":"99","author":"DH Garfield","year":"2007","unstructured":"Garfield DH, Hercbergs A, Davis PJ. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:975\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"38_CR71","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","volume":"340","author":"SI Sherman","year":"1999","unstructured":"Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999;340:1075\u20139.","journal-title":"N Engl J Med"},{"key":"38_CR72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/08880019409141900","volume":"11","author":"R Bessho","year":"1994","unstructured":"Bessho R, Ohta K, Akanuma A, Sakata K. Dosimetry of radiation scattered to thyroid gland from prophylactic cranial irradiation for childhood leukemia. Pediatr Hematol Oncol 1994;11:47\u201353.","journal-title":"Pediatr Hematol Oncol"},{"key":"38_CR73","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ejca.2007.01.036","volume":"43","author":"LM Madanat","year":"2007","unstructured":"Madanat LM, Lahteenmaki PM, Alin J, Salmi TT. The natural history of thyroid function abnormalities after treatment for childhood cancer. Eur J Cancer 2007;43:1161\u201370.","journal-title":"Eur J Cancer"},{"key":"38_CR74","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ctrv.2003.12.003","volume":"30","author":"BA Jereczek-Fossa","year":"2004","unstructured":"Jereczek-Fossa BA, Alterio D, Jassem J, Gibelli B, Tradati N, Orecchia R. Radiotherapy-induced thyroid disorders. Cancer Treat Rev 2004;30:369\u201384.","journal-title":"Cancer Treat Rev"},{"key":"38_CR75","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/(SICI)1097-0142(19970815)80:4<798::AID-CNCR19>3.0.CO;2-O","volume":"80","author":"D Chin","year":"1997","unstructured":"Chin D, Sklar C, Donahue B, Uli N, Geneiser N, Allen J, et al. Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma\/primitive neuroectodermal tumors: a comparison of hyperfractionated versus conventional radiotherapy. Cancer 1997;80:798\u2013804.","journal-title":"Cancer"},{"key":"38_CR76","first-page":"265","volume":"78","author":"MD Littley","year":"1991","unstructured":"Littley MD, Shalet SM, Morgenstern GR, Deakin DP. Endocrine and reproductive dysfunction following fractionated total body irradiation in adults. Quart J Med 1991;78:265\u201374.","journal-title":"Quart J Med"},{"key":"38_CR77","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1210\/jc.2004-0836","volume":"89","author":"H Ishiguro","year":"2004","unstructured":"Ishiguro H, Yasuda Y, Tomita Y, Shinagawa T, Shimizu T, Morimoto T, et al. Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence. J Clin Endocrinol Metab 2004;89:5981\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"38_CR78","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199108293250902","volume":"325","author":"SL Hancock","year":"1991","unstructured":"Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin\u2019s disease. N Engl J Med 1991;325:599\u2013605.","journal-title":"N Engl J Med"},{"key":"38_CR79","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0360-3016(88)90065-X","volume":"14","author":"JS Loeffler","year":"1988","unstructured":"Loeffler JS, Tarbell NJ, Garber JR, Mauch P. The development of Graves\u2019 disease following radiation therapy in Hodgkin\u2019s disease. Int J Radiat Oncol Biol Phys 1988;14:175\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"38_CR80","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00000441-198412000-00005","volume":"288","author":"DR Jacobson","year":"1984","unstructured":"Jacobson DR, Fleming BJ. Grave\u2019s disease with ophthalmopathy following radiotherapy for Hodgkin\u2019s disease. Am J Med Sci 1984;288:217\u201320.","journal-title":"Am J Med Sci"},{"key":"38_CR81","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00520-004-0713-3","volume":"13","author":"KA Al-Anazi","year":"2005","unstructured":"Al-Anazi KA, Inam S, Jeha MT, Judzewitch R. Thyrotoxic crisis induced by cytotoxic chemotherapy. Support Care Cancer 2005;13:196\u20138.","journal-title":"Support Care Cancer"},{"key":"38_CR82","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0003-4266(06)72609-9","volume":"67","author":"N Kabbaj","year":"2006","unstructured":"Kabbaj N, Guedira MM, El Atmani H, El Alaoui M, Mohammadi M, Benabed K, et al. Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study. Ann Endocrinol (Paris) 2006;67:343\u20137.","journal-title":"Ann Endocrinol (Paris)"},{"key":"38_CR83","first-page":"225","volume":"53","author":"S Umemoto","year":"2007","unstructured":"Umemoto S, Izumi K, Kanno H. Two cases of hyperthyroidism induced by interferon-alpha therapy for renal cell carcinoma. Hinyokika Kiyo 2007;53:225\u20139. (article in Japanese).","journal-title":"Hinyokika Kiyo"},{"key":"38_CR84","first-page":"3227","volume":"85","author":"C Sklar","year":"2000","unstructured":"Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, et al. Abnormalities of the thyroid in survivors of Hodgkin\u2019s disease: data from the childhood cancer survivor study. J Clin Endocrinol Metab 2000;85:3227\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"38_CR85","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0360-3016(96)00480-4","volume":"6","author":"K Nishiyama","year":"1996","unstructured":"Nishiyama K, Kozuka T, Higashihara T, Miyauchi K, Okagawa K. Acute radiation thyroiditis. Int J Radiat Oncol Biol Phys 1996;6:1221\u20134.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"38_CR86","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/00002018-200528090-00003","volume":"28","author":"J Atsmon","year":"2005","unstructured":"Atsmon J, Dolev E. Drug-induced hypomagnesaemia: scope and management. Drug Safety 2005;28:763\u201388.","journal-title":"Drug Safety"},{"key":"38_CR87","first-page":"105","volume":"23","author":"M Elisaf","year":"1997","unstructured":"Elisaf M, Milionis H, Siamipoulos KC. Hypomagnesemic hypokalemia and hypocalcemia: clinical and laboratory characteristics. Miner Electrolyte Metab 1997;23:105\u201312.","journal-title":"Miner Electrolyte Metab"},{"key":"38_CR88","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1001\/archinte.1984.00350220063013","volume":"114","author":"JE Buckley","year":"1984","unstructured":"Buckley JE, Clark VL, Meyer TJ, Pearlman NW. Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med 1984;114:2347\u20138.","journal-title":"Arch Intern Med"},{"key":"38_CR89","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/pbc.20812","volume":"48","author":"W St\u00f6hr","year":"2007","unstructured":"St\u00f6hr W, Paulides M, Bielack S, J\u00fcrgens H, Koscielniak E, Rossi R, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 2007;48:140\u20137.","journal-title":"Pediatr Blood Cancer"},{"key":"38_CR90","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/archinte.1980.00330220069024","volume":"140","author":"NW Lyman","year":"1980","unstructured":"Lyman NW, Hemalatha C, Viscuso RL, Jacobs MG. Cisplatin-induced hypocalcemia and hypomagnesemia. Arch Intern Med 1980;140:1512\u20134.","journal-title":"Arch Intern Med"},{"key":"38_CR91","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00280-002-0556-x","volume":"51","author":"K Baeksgaard","year":"2003","unstructured":"Baeksgaard K, Sorensen JB. Acute tumor lysis syndrome in solid tumors\u2014a case report and review of the literature. Cancer Chemother Pharmacol 2003;51:187\u201392.","journal-title":"Cancer Chemother Pharmacol"},{"key":"38_CR92","first-page":"186","volume":"11","author":"H Furue","year":"1984","unstructured":"Furue H. Interferons\u2014its method of administration and adverse effect related to pharmacokinetics. Gan to Kagaku Ryoho 1984;11:186\u201393. (article in Japanese).","journal-title":"Gan to Kagaku Ryoho"},{"key":"38_CR93","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1345\/aph.1D357","volume":"38","author":"T Tanvetyanon","year":"2004","unstructured":"Tanvetyanon T, Choudhury AM. Hypocalcemia and azootemia associated with zoledronic acid and interferon alfa. Ann Pharmacother 2004;38:418\u201321. (Epub 2004 Jan 23).","journal-title":"Ann Pharmacother"},{"key":"38_CR94","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/1097-0142(197509)36:3<1111::AID-CNCR2820360341>3.0.CO;2-9","volume":"36","author":"IB Rosen","year":"1975","unstructured":"Rosen IB, Strawbridge HG, Bain J. A case of hyperparathyroidism associated with radiation to the head and neck area. Cancer 1975;36:1111\u20134.","journal-title":"Cancer"},{"key":"38_CR95","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.surg.2004.06.042","volume":"136","author":"AE Stephen","year":"2004","unstructured":"Stephen AE, Chen KT, Milas M, Siperstein AE. The coming of age of radiation-induced hyperparathyroidism: evolving patterns of thyroid and parathyroid disease after head and neck irradiation. Surgery 2004;136:1143\u201353.","journal-title":"Surgery"},{"key":"38_CR96","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF01658376","volume":"8","author":"I Hedman","year":"1984","unstructured":"Hedman I, Hansson G, Lundberg LM, Tisel LE. A clinical evaluation of radiation-induced hyperparathyroidism based on 148 surgically treated patients. World J Surg 1984;8:96\u2013105.","journal-title":"World J Surg"},{"key":"38_CR97","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00000441-197911000-00006","volume":"278","author":"V Fiorica","year":"1979","unstructured":"Fiorica V, Males JL. Hyperparathyroidism after radiation of the neck: a case report and review of the literature. Am J Med Sci 1979;278:223\u20138.","journal-title":"Am J Med Sci"},{"key":"38_CR98","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2273.1999.00214.x","volume":"24","author":"MA Thorp","year":"1999","unstructured":"Thorp MA, Levitt NS, Mortimore S, Isaacs S. Parathyroid and thyroid function five years after treatment of laryngeal and hypopharyngeal carcinoma. Clin Otolaryngol Allied Sci 1999;24:104\u20138.","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"38_CR99","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jat.1221","volume":"27","author":"PW Harvey","year":"2007","unstructured":"Harvey PW, Everett DJ, Springall CJ. Adrenal toxicity: a strategy for assessment of functional toxicity to the adrenal cortex and steroidogenesis. J Appl Toxicol 2007;27:103\u201315.","journal-title":"J Appl Toxicol"},{"key":"38_CR100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0268-960X(02)00042-5","volume":"16","author":"SC Howard","year":"2002","unstructured":"Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002;16:225\u201343.","journal-title":"Blood Rev"},{"key":"38_CR101","first-page":"386","volume":"6","author":"S Hahner","year":"2005","unstructured":"Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 2005;6:386\u201394.","journal-title":"Curr Opin Investig Drugs"},{"key":"38_CR102","first-page":"55","volume":"65","author":"CI Ditzhuijsen van","year":"2007","unstructured":"van Ditzhuijsen CI, van der Weijer R, Haak HR. Adrenocorticol carcinoma. Neth J Med 2007;65:55\u201360.","journal-title":"Neth J Med"},{"key":"38_CR103","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2005-2639","volume":"91","author":"B Allolio","year":"2006","unstructured":"Allolio B, Fassnacht M. Clinical review: Adrenocorticol carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027\u201337.","journal-title":"J Clin Endocrinol Metab"},{"key":"38_CR104","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMe078087","volume":"356","author":"DE Schteingart","year":"2007","unstructured":"Schteingart DE. Adjuvant mitotane therapy of adrenal cancer\u2014use and controversy. N Engl J Med 2007;356:2415\u20138.","journal-title":"N Engl J Med"},{"key":"38_CR105","doi-asserted-by":"crossref","first-page":"154","DOI":"10.7326\/0003-4819-64-1-154","volume":"64","author":"RV Smalley","year":"1966","unstructured":"Smalley RV, Wall RL. Two cases of busulfan toxicity. Ann Intern Med 1966;64:154\u201364.","journal-title":"Ann Intern Med"},{"key":"38_CR106","doi-asserted-by":"crossref","first-page":"654","DOI":"10.7326\/0003-4819-63-4-654","volume":"63","author":"HN Ward","year":"1965","unstructured":"Ward HN, Konikov N, Reinhard EH. Cytologic dysplasia occurring after busulfan (Myleran) therapy. A syndrome resembling adrenocorticol insufficiency and atrophic bronchitis. Ann Intern Med 1965;63:654\u201360.","journal-title":"Ann Intern Med"},{"key":"38_CR107","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.V18.5.497.497","volume":"18","author":"RA Kyle","year":"1961","unstructured":"Kyle RA, Schwartz RS, Oliner HL, Dameshek W. A syndrome resembling adrenal corticol insufficiency associated with long term busulfan (Myleran) therapy. Blood 1961;18:497\u2013510.","journal-title":"Blood"},{"key":"38_CR108","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/bmj.1.5485.463","volume":"1","author":"BP Harrold","year":"1966","unstructured":"Harrold BP. Syndrome resembling Addison\u2019s disease following prolonged treatment with busulphan. Br Med J 1966;1:463\u20134.","journal-title":"Br Med J"},{"key":"38_CR109","unstructured":"GlaxoSmithKline. Myleran, Prescribing Information. Jan 2004. GlaxoSmithKline."},{"key":"38_CR110","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367\u201373.","journal-title":"Clin Cancer Res"},{"key":"38_CR111","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1002\/(SICI)1097-0142(19961201)78:11<2411::AID-CNCR20>3.0.CO;2-2","volume":"78","author":"K Kobayashi","year":"1996","unstructured":"Kobayashi K, Weiss RE, Vogelzang NJ, Vokes EE, Janisch L, Ratain MJ. Mineralocorticoid insufficiency due to suramin therapy. Cancer 1996;78:2411\u201320.","journal-title":"Cancer"},{"key":"38_CR112","first-page":"1100","volume":"110","author":"K Dorfinger","year":"1991","unstructured":"Dorfinger K, Niederle B, Vierhapper H, Astrid W, Czernin S, Nowotny P, et al. Suramin and the human adrenocortex: results of experimental and clinical studies. Surgery 1991;110:1100\u20135.","journal-title":"Surgery"},{"key":"38_CR113","doi-asserted-by":"crossref","first-page":"843","DOI":"10.7326\/0003-4819-122-11-199506010-00006","volume":"122","author":"MC Leinung","year":"1995","unstructured":"Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995;122:843\u20135.","journal-title":"Ann Intern Med"},{"key":"38_CR114","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/asheducation-2002.1.422","volume":"1","author":"JR Wingard","year":"2002","unstructured":"Wingard JR, Vogelsang GB, Deeg HJ. Stem sell transplantation: supportive care and long-term complications. Hematology 2002;1:422\u201344.","journal-title":"Hematology"},{"key":"38_CR115","first-page":"326","volume":"53","author":"M Schmiegelow","year":"2006","unstructured":"Schmiegelow M. Endocrinological late effects following radiotherapy and chemotherapy of childhood brain tumours. Dan Med Bull 2006;53:326\u201341.","journal-title":"Dan Med Bull"},{"key":"38_CR116","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.soncn.2006.11.006","volume":"23","author":"CT Stricker","year":"2007","unstructured":"Stricker CT. Endocrine effects of breast cancer treatment. Sem Oncol Nurs 2007;23:55\u201370.","journal-title":"Sem Oncol Nurs"},{"key":"38_CR117","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1200\/JCO.2006.07.2793","volume":"24","author":"JM Walshe","year":"2006","unstructured":"Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006;24:5769\u201379.","journal-title":"J Clin Oncol"},{"key":"38_CR118","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mpo.2950170510","volume":"17","author":"WH Wallace","year":"1989","unstructured":"Wallace WH, Shalet SM, Crowne EC, Morris-Jones PH, Gattamaneni HR, Price DA. Gonadal dysfunction due to cis-platinum. Med Pediatr Oncol 1989;17:409\u201313.","journal-title":"Med Pediatr Oncol"},{"key":"38_CR119","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/02841860601166958","volume":"46","author":"M Brydoy","year":"2007","unstructured":"Brydoy M, Fossa SD, Dahl O, Bjoro T. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol 2007;46:480\u20139.","journal-title":"Acta Oncol"},{"key":"38_CR120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0277-5379(85)90088-4","volume":"21","author":"S Viviani","year":"1985","unstructured":"Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin\u2019s disease. Comparative results of MOPP vs. ABVD. Eur J Cancer Clin Oncol 1985;21:601\u20135.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"38_CR121","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0889-8529(05)70048-7","volume":"27","author":"S Howell","year":"1998","unstructured":"Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998;27:927\u201343.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"38_CR122","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.1999.17.5.1493","volume":"17","author":"SJ Howell","year":"1999","unstructured":"Howell SJ, Radford JA, Ryder WD, Shalet SM. Testicular function after cytotoxic chemotherapy; evidence of Leydig cell insufficiency. J Clin Oncol 1999;17:493\u20138.","journal-title":"J Clin Oncol"},{"key":"38_CR123","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/1097-0142(20010401)91:7<1297::AID-CNCR1132>3.0.CO;2-Z","volume":"91","author":"A Gerl","year":"2001","unstructured":"Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W. The impact of chemotherapy on Leydig cell function in long-term survivors of germ cell tumors. Cancer 2001;91:1297\u20131303.","journal-title":"Cancer"},{"key":"38_CR124","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00008480-200108000-00011","volume":"13","author":"HK Gleeson","year":"2001","unstructured":"Gleeson HK, Shalet SM. Endocrine complications of neoplastic diseases in children and adolescents. Curr Opin Pediatr 2001;13:346\u201351.","journal-title":"Curr Opin Pediatr"},{"key":"38_CR125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jncimonographs\/lgi003","volume":"34","author":"SJ Howell","year":"2005","unstructured":"Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 2005;34:12\u20137.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"38_CR126","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<2020::AID-CNCR25>3.0.CO;2-Y","volume":"78","author":"J Heikens","year":"1996","unstructured":"Heikens J, Behrendt H, Adriaanse R, Berghout A. Irreversible gonadal damage in male survivors of pediatric Hodgkin\u2019s disease. Cancer 1996;78:2020\u20134.","journal-title":"Cancer"},{"key":"38_CR127","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1200\/JCO.1996.14.11.2923","volume":"14","author":"C Bokemeyer","year":"1996","unstructured":"Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14:2923\u201332.","journal-title":"J Clin Oncol"},{"key":"38_CR128","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2217::AID-CNCR22>3.0.CO;2-J","volume":"83","author":"GL Bramswig","year":"1998","unstructured":"Bramswig GL, Shlegel W, Jurgens H, Schellong G. The effects of etoposide on testicular function in boys treated for Hodgkin\u2019s disease. Cancer 1998;83:2217\u201322.","journal-title":"Cancer"},{"key":"38_CR129","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.eururo.2007.05.012","volume":"52","author":"P Wiechno","year":"2007","unstructured":"Wiechno P, Demkow T, Kubiak K, Sadowska M, Kaminska J. The quality of life and hormonal disturbances in testicular cancer survivors in cisplatin era. Eur Urol 2007;52:1448\u201354.","journal-title":"Eur Urol"},{"key":"38_CR130","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/bjc.1996.213","volume":"73","author":"CC Berger","year":"1996","unstructured":"Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 1996;73:1108\u201314.","journal-title":"Br J Cancer"},{"key":"38_CR131","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.49.2.498","volume":"47","author":"W Arlt","year":"1997","unstructured":"Arlt W, Hove U, Muller B, Reincke M, Berweiler U, Schwab F, et al. Frequent and frequently overlooked: treatment-induced endocrine dysfunction in adult long-term survivors of primary brain tumors. Neurology 1997;47:498\u2013506.","journal-title":"Neurology"},{"key":"38_CR132","first-page":"284","volume":"50","author":"CJ Bryce","year":"1998","unstructured":"Bryce CJ, Shenkier T, Gelmon K. Menstrual disruption in premenopausal breast cancer patients receiving CMF (IV) vs. AC adjuvant chemotherapy. Breast Cancer Res Treat 1998;50:284.","journal-title":"Breast Cancer Res Treat"},{"key":"38_CR133","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/107327480200900603","volume":"9","author":"SE Minton","year":"2002","unstructured":"Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002;9:466\u201372.","journal-title":"Cancer Control"},{"key":"38_CR134","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","volume":"14","author":"J Bines","year":"1996","unstructured":"Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718\u201329.","journal-title":"J Clin Oncol"},{"key":"38_CR135","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1200\/JCO.2005.03.3969","volume":"24","author":"JA Petrek","year":"2006","unstructured":"Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006;24:1045\u201351.","journal-title":"J Clin Oncol"},{"key":"38_CR136","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/107327480200900603","volume":"9","author":"SE Minton","year":"2002","unstructured":"Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002;9:466\u201372.","journal-title":"Cancer Control"},{"key":"38_CR137","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1634\/theoncologist.11-2-96","volume":"11","author":"MT Knobf","year":"2006","unstructured":"Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. The Oncologist 2006;11:96\u2013110.","journal-title":"The Oncologist"},{"key":"38_CR138","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01.coc.0000251398.57630.4f","volume":"30","author":"YL Tham","year":"2007","unstructured":"Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007;30:126\u201332.","journal-title":"Am J Clin Oncol"},{"key":"38_CR139","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1021609530248","volume":"20","author":"U Monga","year":"2002","unstructured":"Monga U. Sexual functioning in cancer patients. Sex Disabil 2002;20:277\u201395.","journal-title":"Sex Disabil"},{"key":"38_CR140","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/cncr.10773","volume":"95","author":"L Tauchmanova","year":"2002","unstructured":"Tauchmanova L, Selleri C, DeRosa G, Pagano L, Orio F, Lombardi G, et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 2002;95:1076\u201384.","journal-title":"Cancer"},{"key":"38_CR141","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bmt.1701075","volume":"21","author":"E Thibaud","year":"1998","unstructured":"Thibaud E, Rodriguez-Macias K, Trivin C, Esperou H, Michon J, Brauner R. Ovarian function after bone marrow transplantation during childhood. Bone Marrow Transplant 1998;21:287\u201390.","journal-title":"Bone Marrow Transplant"},{"key":"38_CR142","first-page":"2758","volume-title":"Cancer, principles and practice of oncology","author":"ML Meistrich","year":"1997","unstructured":"Meistrich ML, Vassilopoulou-Sellin R, Lipschultz LI. Adverse effects of treatment: gonadal dysfunction. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 5th ed. New York: Lippincott-Raven; 1997. p. 2758\u201373.","edition":"5"},{"key":"38_CR143","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1006\/faat.1996.0164","volume":"33","author":"AM Standeven","year":"1996","unstructured":"Standeven AM, Beard RL, Johnson AT, Boehm MF, Escobar M, Heyman RA, et al. Retinoid-induced hypertriglyceridemia in rats is mediated by retinoic Acid receptors. Fundam Appl Toxicol 1996;33:264\u201372.","journal-title":"Fundam Appl Toxicol"},{"key":"38_CR144","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/neuonc\/3.1.35","volume":"3","author":"RO Dillman","year":"2001","unstructured":"Dillman RO, Shea WM, Tai DF, Mahdavi K, Barth NM, Kharkar BR, et al. Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Neuro-Oncol 2001;3:35\u201341.","journal-title":"Neuro-Oncol"},{"key":"38_CR145","doi-asserted-by":"crossref","first-page":"582","DOI":"10.7326\/0003-4819-136-8-200204160-00007","volume":"136","author":"N Rodondi","year":"2002","unstructured":"Rodondi N, Darioli R, Ramelet AA, Hohl D, Lenain V, Perdrix J, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic therapy for acne: a pharmacogenetic study. Ann Intern Med 2002;136:582\u20139.","journal-title":"Ann Intern Med"},{"key":"38_CR146","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.metabol.2003.07.006","volume":"53","author":"D Stoll","year":"2004","unstructured":"Stoll D, Binnert C, Mooser V, Tappy L. Short-term administration of isotretinoin elevates plasma triglyceride concentrations without affecting insulin sensitivity in health humans. Metabolism 2004;53:4\u201310.","journal-title":"Metabolism"},{"key":"38_CR147","unstructured":"Hoffman-La Roche Inc. Roferon-A, Complete product information. Sept 2003."},{"key":"38_CR148","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/ajh.2830490311","volume":"49","author":"MJ Pe\u00f1arrubia","year":"1995","unstructured":"Pe\u00f1arrubia MJ, Steegmann JL, Lavilla E, Casado F, Requena MJ, Pic\u00f5 M, et al. Hypertriglyceridemia may be severe in CML patients treated with interferon-alpha. Am J Hematol 1995;49:240\u20131.","journal-title":"Am J Hematol"},{"key":"38_CR149","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1345\/aph.1D546","volume":"38","author":"SF Wong","year":"2004","unstructured":"Wong SF, Jakowatz JG, Taheri R. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma. Ann Pharmacother 2004;38:1655\u20139.","journal-title":"Ann Pharmacother"},{"key":"38_CR150","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.1992.10.9.1386","volume":"10","author":"D Raghavan","year":"1992","unstructured":"Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992;10:1375\u20139.","journal-title":"J Clin Oncol"},{"key":"38_CR151","doi-asserted-by":"crossref","first-page":"709","DOI":"10.7326\/0003-4819-116-9-709","volume":"116","author":"JA Gietema","year":"1992","unstructured":"Gietema JA, Sleijfer DT, Willemse PH, Scraffordt Koops H, van Ittersum E, Verschuren WM, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992;116:709\u201315.","journal-title":"Ann Intern Med"},{"key":"38_CR152","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/S0022-5347(05)64274-7","volume":"168","author":"DW Fenton","year":"2002","unstructured":"Fenton DW, Verma S, Venner P, Sawhney R, Mackey JR. The lack of long-term effect of cisplatin based combination chemotherapy on serum cholesterol for treatment of testicular cancer. J Urol 2002;168:1971\u20134.","journal-title":"J Urol"},{"key":"38_CR153","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1055\/s-2007-1003770","volume":"23","author":"R Vassilopoulou-Sellin","year":"1991","unstructured":"Vassilopoulou-Sellin R, Samaan NA. Mitotane administration: an unusual cause of hypercholesterolemia. Horm Metab Res 1991;23:619\u201320.","journal-title":"Horm Metab Res"},{"key":"38_CR154","first-page":"1297","volume":"11","author":"S Toma","year":"2004","unstructured":"Toma S, Bonelli L, Sartoris A, Mira E, Antonelli A, Beatrice F, et al. 13-cis Retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. Oncol Rep 2004;11:1297\u2013305.","journal-title":"Oncol Rep"},{"key":"38_CR155","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood.V89.6.1886","volume":"89","author":"SK Parsons","year":"1997","unstructured":"Parsons SK, Skapek SX, Neufeld EJ, Kuhlman C, Young ML, Donnelly M, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 1997;89:1886\u201395.","journal-title":"Blood"},{"key":"38_CR156","first-page":"671","volume":"84","author":"VM Maher","year":"1992","unstructured":"Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR, Besser GM. Possible mechanism and treatment of o,p\u2032DDD-induced hypercholesterolaemia. Q J Med 1992;84:671\u20139.","journal-title":"Q J Med"},{"key":"38_CR157","first-page":"102","volume":"97","author":"O Lasa","year":"2006","unstructured":"Lasa O, Izu R, Acebo E, Eguino P, D\u00edaz-P\u00e9rez JL. Treatment of cutaneous T-cell lymphomas with bexarotene. Actas Dermo-sifiliogr 2006;97:102 (article in Spanish).","journal-title":"Actas Dermo-sifiliogr"},{"key":"38_CR158","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200001040-00006","volume":"1","author":"MN Lowe","year":"2000","unstructured":"Lowe MN, Plosker GL. Bexarotene. Am J Clin Dermatol 2000;1:245\u201350. (discussion 251\u20132).","journal-title":"Am J Clin Dermatol"},{"key":"38_CR159","first-page":"256","volume":"15","author":"B Zalewska-Szewczyk","year":"2003","unstructured":"Zalewska-Szewczyk B, Przybysz K, Kowalewska-Pietrzak M, Stolarska M, Bodalski J. Iatrogenic hyperlipidemia after l-asparaginase and glucocorticoid treatment in two children with acute lymphoblastic leukemia. Pol Merkur Lekarski 2003;15:256\u20138. (article in Polish).","journal-title":"Pol Merkur Lekarski"},{"key":"38_CR160","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1442-200x.2004.01991.x","volume":"46","author":"F Athanassiadou","year":"2004","unstructured":"Athanassiadou F, Kourti M, Papageorgiou T, Stamou M, Makedou A, Boufidou A. Severe hyperlipidemia in a child with acute lymphoblastic leukemia treated with l-asparaginase and prednisone. Pediatr Int 2004;46:743\u20134.","journal-title":"Pediatr Int"},{"key":"38_CR161","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/1097-0142(19941215)74:12<3234::AID-CNCR2820741224>3.0.CO;2-1","volume":"74","author":"PG Steinherz","year":"1994","unstructured":"Steinherz PG. Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. Cancer 1994;74:3234\u20139.","journal-title":"Cancer"},{"key":"38_CR162","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1592\/phco.24.5.508.33355","volume":"24","author":"T Iwamoto","year":"2004","unstructured":"Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M. Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy 2004;24:508\u201314.","journal-title":"Pharmacotherapy"},{"key":"38_CR163","doi-asserted-by":"crossref","first-page":"61N","DOI":"10.1016\/S0002-9343(89)80932-5","volume":"87","author":"MS Markell","year":"1989","unstructured":"Markell MS, Friedman EA. Hyperlipidemia after organ transplantation. Am J Med 1989;87:61N\u20137N.","journal-title":"Am J Med"},{"key":"38_CR164","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1023\/B:DDAS.0000011598.15105.58","volume":"49","author":"M Deters","year":"2004","unstructured":"Deters M, Kirchner G, Koal T, Resch K, Kaever V. Everolimus\/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rates. Dig Dis Sci 2004;49:30\u20137.","journal-title":"Dig Dis Sci"},{"key":"38_CR165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.tp.0000188177.21406.97","volume":"81","author":"MH Moghadasian","year":"2006","unstructured":"Moghadasian MH. Dietary phytosterols reduce cyclosporine-induced hypercholesterolemia in apolipoprotein E-knockout mice. Transplantation 2006;81:207\u201313.","journal-title":"Transplantation"},{"key":"38_CR166","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5483\/BMBRep.2002.35.1.054","volume":"35","author":"MS Lee","year":"2002","unstructured":"Lee MS. Cytokine synergism in apoptosis: its role in diabetes and cancer. J Biochem Mol Biol 2002;35:54\u201360.","journal-title":"J Biochem Mol Biol"},{"key":"38_CR167","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2337\/diab.38.5.641","volume":"38","author":"VA Koivisto","year":"1989","unstructured":"Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989;38:641\u20137.","journal-title":"Diabetes"},{"key":"38_CR168","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0140-6736(92)91744-S","volume":"340","author":"P Fabris","year":"1992","unstructured":"Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992;340:548.","journal-title":"Lancet"},{"key":"38_CR169","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.2337\/diacare.21.10.1774a","volume":"10","author":"G Tohda","year":"1998","unstructured":"Tohda G, Oida K, Higashi S, Hayashi T, Miyamori I. Interferon-alpha and development of type 1 diabetes: a case without insulin resistance. Diabetes Care 1998;10:1774.","journal-title":"Diabetes Care"},{"key":"38_CR170","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2036.2003.01681.x","volume":"18","author":"P Fabris","year":"2003","unstructured":"Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549\u201358.","journal-title":"Aliment Pharmacol Ther"},{"key":"38_CR171","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0168-8278(98)80328-0","volume":"28","author":"P Fabris","year":"1998","unstructured":"Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998;28:514\u20137.","journal-title":"J Hepatol"},{"key":"38_CR172","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0268-960X(02)00042-5","volume":"16","author":"SC Howard","year":"2002","unstructured":"Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002;16:225\u201343.","journal-title":"Blood Rev"},{"key":"38_CR173","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/diaspect.19.3.157","volume":"19","author":"HM Psarakis","year":"2006","unstructured":"Psarakis HM. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectr 2006;19:157\u201362.","journal-title":"Diabetes Spectr"},{"key":"38_CR174","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0950-351X(05)80170-3","volume":"6","author":"RE Ferner","year":"1992","unstructured":"Ferner RE. Drug-induced diabetes. Baillieres Clin Endocrinol Metab 1992;6:849\u201366.","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"38_CR175","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/1097-0142(197410)34:4<993::AID-CNCR2820340404>3.0.CO;2-T","volume":"34","author":"PS Schein","year":"1974","unstructured":"Schein PS, O, Connell MJ, Blom J, Hubbard S, Magrath IT, Bergevin P, et al. Clinical antitumor activity and toxicity of streptozocin (NSC-85998). Cancer 1974;34:993\u20131000.","journal-title":"Cancer"},{"key":"38_CR176","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1385\/IJGC:35:3:179","volume":"35","author":"ME Pavel","year":"2005","unstructured":"Pavel ME, Baum U, Hahn EG, Hensen J. Doxorubicin and streptozocin after failed biotherapy for neuroendocrine tumors. Int J Gastrointest Cancer 2005;35:179\u201385.","journal-title":"Int J Gastrointest Cancer"},{"key":"38_CR177","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-118-7-199304010-00008","volume":"118","author":"MK Pandit","year":"1993","unstructured":"Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993;118:529\u201339.","journal-title":"Ann Intern Med"},{"key":"38_CR178","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0165-2478(85)90051-3","volume":"10","author":"C Sestier","year":"1985","unstructured":"Sestier C, Odent-Pogu S, Bonneville M, Maurel C, Lang F, Sai P. Cyclosporin enhances diabetes induced by low-dose streptozotocin treatment in mice. Immunol Lett 1985;10:57\u201360.","journal-title":"Immunol Lett"},{"key":"38_CR179","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271\u201381.","journal-title":"N Engl J Med"},{"key":"38_CR180","unstructured":"Duran I, Le L, Saltman D, Singh W, Kocha R, Cheiken G, et al. A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs, Abstract no: 146). 2005, Jan. 27\u20139. Gastrointestinal Cancers Symposium, Hollywood, FL, USA."},{"key":"38_CR181","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","volume":"95","author":"I Duran","year":"2006","unstructured":"Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148\u201354.","journal-title":"Br J Cancer"},{"key":"38_CR182","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/01.cad.0000168394.89428.11","volume":"16","author":"S Ferrari","year":"2005","unstructured":"Ferrari S, Pieretti F, Verri E, Tolentinis L, Cedari M, Versari M, et al. Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cistplatin and high-dose methotrexate. Anticancer Drugs 2005;16:733\u20138.","journal-title":"Anticancer Drugs"},{"key":"38_CR183","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1054\/bjoc.2000.1214","volume":"82","author":"R Skinner","year":"2000","unstructured":"Skinner R, Coterrill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. Br J Cancer 2000;82:1636\u201345.","journal-title":"Br J Cancer"},{"key":"38_CR184","doi-asserted-by":"crossref","unstructured":"Feuerstein M, editor. Handbook of cancer survivorship. New York, Springer; 2007.","DOI":"10.1007\/978-0-387-34562-8"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-007-0038-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11764-007-0038-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-007-0038-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T10:46:40Z","timestamp":1588070800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11764-007-0038-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,20]]},"references-count":184,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,11,28]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1007\/s11764-007-0038-6","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,20]]}}}